Skip to main content
. 2022 Jan 4;132(1):e150051. doi: 10.1172/JCI150051

Figure 3. SIRT6 suppresses osteogenic transdifferentiation of VSMCs via regulation of Runx2.

Figure 3

(A) Expression levels of α-SMA and OPN in abdominal arteries of indicated groups were determined by IF staining (n = 4 per group). Scale bars: 50 μm. (B) Western blot analysis of osteogenic and contractile property factors expression in abdominal arteries (n = 3 per group). (C) Analysis of osteogenic and contractile property factor expression in WT and SIRT6-Tg VSMCs after Pi (3.0 mM) treatment by Western blot (n = 4 per group). (D) VSMCs were pretransfected with siSIRT6 or siNC, and then incubated with Pi (3.0 mM) for 7 days, and the downstream osteogenic markers (OPN, OCN) and contractile property markers (α-SMA, SM22α) were analyzed by Western blot (n = 4 per group). (E) Runx2 expression was analyzed in WT and SIRT6-Tg VSMCs after Pi (3.0 mM) treatment by Western blot (n = 4 per group). (F–H) SIRT6-Tg VSMCs were pretransfected with Runx2 plasmid or vector plasmid, and then exposed to Pi (3.0 mM) for 7 days. The expression of SIRT6 and Runx2 were analyzed by Western blot (F). VSMCs were stained for mineralization by Alizarin red S (G), and osteogenic markers (OPN, OCN) and contractile property markers (α-SMA, SM22α) were analyzed by qPCR (n = 3 per group) (H). Statistical significance was assessed using 1-way ANOVA followed by Dunnett’s test (H). *P < 0.05. All values are mean ± SD.